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Fatty-acid-binding protein 3, muscle and heart (FABP3), also known as heart-type FABP, is a member
of the family of intracellular lipid-binding proteins. It is a small cytoplasmic protein with a molec-
ular mass of about 15 kDa. FABPs are known to be carrier proteins for transporting fatty acids and
other lipophilic substances from the cytoplasm to the nucleus, where these lipids are released to a
group of nuclear receptors such as peroxisome proliferator-activated receptors (PPARs). In this
study, using lysophosphatidic acid (LPA)-coated agarose beads, we have identiﬁed FABP3 as an
LPA carrier protein in human coronary artery endothelial cells (HCAECs). Administration of LPA
to HCAECs resulted in a dose-dependent increase in PPARc activation. Furthermore, the LPA-
induced PPARc activation was abolished when the FABP3 expression was reduced using small inter-
fering RNA (siRNA). We further show that the nuclear fraction of control HCAECs contained a signif-
icant amount of exogenously added LPA, whereas FABP3 siRNA-transfected HCAECs had a decreased
level of LPA in the nucleus. Taken together, these results suggest that FABP3 governs the transcrip-
tional activities of LPA by targeting them to cognate PPARc in the nucleus.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Fatty-acid-binding protein 3, muscle and heart (FABP3) is one of
nine known cytosolic FABPs ranging in size from 14 to 15 kDa. It is
most ubiquitously expressed in heart, skeletalmuscle, and other tis-
sues [1,2]. Theprotein is involved inmaintaininganenergy supply to
the heart [3] and other body parts [4], as well as in regulating the
intramuscular fat content [5] and improving insulin sensitivity [6].
Shan et al. reported FABP3 works as being the response gene of
peroxisome proliferator-activated receptor gamma (PPARc) [7].
PPARc is a member of the nuclear hormone receptor superfamily,
many members of which function as lipid-activated transcription
factors [8]. These gene regulatory factors have a direct impact on
human diseases such as atherosclerosis, obesity, diabetes, and can-cer [9–12]. Gene transcription by PPARc has been shown to be reg-
ulated by ligands such as retinoic acid and long-chain fatty acids
[13], which bind in cells to members of the family of intracellular
lipid binding proteins, including FABPs. Published X-ray crystal
structures of FABPs have revealed that the entrance to the
ligand-binding pockets is ﬂanked by two a-helices that appear to
limit access to the binding site [14]. In this study, we show that
lysophosphatidic acid (LPA)-bound FABP3 can be displaced by
LPA but not by lysophosphatidylcholine (LPC). Previous studies
have provided evidence that LPA is an intracellular agonist for
PPARc, and might enter cells to activate the PPARc. In the inacti-
vated state, PPARc is believed to exist as complexes, bound with
corepressor proteins such as nuclear receptor corepressor and
silencing mediator of retinoid [8]. In this state, PPARc may have
a cytoplasmic rather than a nuclear location. Upon ligand activa-
tion, PPARc dissociates from the corepressor and recruits coactiva-
tors [15]. However, the important question that remains to be
answered is how lipids like the poorly water-soluble LPA reach
the nucleus to bind to PPARc and initiate transcriptional activity.
Here, we present evidence that FABP3 functions as an intracellular
carrier for LPA.
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Fig. 1. Silver-stained polyacrylamide gel (4–20%) revealing proteins retained by
lysophosphatidic acid (LPA) beads. (A) Samples of 1 mL (0.5 mg) of cytosolic
proteins were mixed with either control beads or LPA beads. Proteins retained by
the beads were eluted with 30 lM LPA and separated by SDS–PAGE. Molecular
mass markers are shown on the left. The separated protein bands were visualized
by silver staining. The protein band (⁄) was excised from the gel, digested with
trypsin, and identiﬁed by mass ﬁngerprinting. The number of peptides, percentage
of sequence coverage, and the accession number for the protein are given on the
right side. (B) Speciﬁcity of heart-type fatty-acid-binding protein (FABP3) binding to
LPA. The human coronary artery endothelial cell lysates were preincubated with 0,
10, or 30 lM LPA (18:1) or LPC (18:1) before incubation with LPA beads.
Supernatants were analyzed by immunoblotting, using an antibody against FABP3.
Incubation with an anti-b-actin antibody was used as a protein-loading control.
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2.1. Reagents and antibodies
LPA-coated agarose beads (L-6101) and control beads (P-B000)
were purchased from Echelon Biosciences (Salt Lake City, UT, USA).
The tissue culture media were obtained from Nacalai Tesque
(Kyoto, Japan). Rabbit polyclonal antibody against cardiac FABP
(ab45966) was purchased from Abcam (Cambridge, UK), and
mouse polyclonal antibody against b-actin (sc-47778) was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.2. Cell culture
Primary HCAECs (Lonza, Walkersville, MD, USA) were propa-
gated in endothelial cell growth medium (EGM-2) containing 5%
fetal bovine serum, manufacturer-recommended supplemental
growth factors (EGM-2 BulletKit), antibiotics, and antimycotics.
All assays were performed using cells taken between passages 3
and 12 at 60–80% conﬂuence, and were repeated at least three
times in duplicate or triplicate.
2.3. Pull-down assay with LPA beads
HCAECs (1.0  106 cells) were lysed on ice for 30 min in a cell
lysis buffer (20 mM Tris–HCl [pH 7.4], 10% [v/v] glycerol,100 mMNaCl, 1% [v/v] Triton X-100, 1:100 protease inhibitor cock-
tail [Sigma–Aldrich], and 1 mM dithiothreitol) and then centri-
fuged at 16,000g for 20 min at 4 C. The resulting cytosolic
extracts were assayed for pull-down. One milliliter of cytoplasmic
extraction from HCAECs was incubated with 20 lL of the LPA beads
at 4 C for 1 h in lysis buffer. The beads were washed ﬁve times
with a wash buffer (20 mM 2-(N-morpholino)ethanesulfonic acid
[pH 7.4] and 150 mM NaCl), and the proteins were eluted with
30 lM LPA in the wash buffer. Samples were separated on a 5–
20% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) gel and silver stained (WAKO, Tokyo, Japan).
2.4. In-gel digestion and protein identiﬁcation by matrix-assisted laser
desorption/ionization-time-of-ﬂight mass spectrometry
In-gel digestion of gel bands was performed as described previ-
ously [16]. Brieﬂy, protein spots excised from the gel were
destained with 100 mM ammonium bicarbonate in 50% acetoni-
trile. The gel pieces were dried and digested with sequencing-
grade modiﬁed trypsin (Promega). The peptide solution was recov-
ered, and residual peptides were extracted by shaking the solution
with 5% triﬂuoroacetic acid (TFA) in 50% acetonitrile. The combined
solutions were concentrated using a lyophilizer. The tryptic pep-
tides, which were dissolved in 0.1% TFA, were desalted with Zip-
Tip (Millipore, Billerica, MA, USA) according to the manufacturer’s
instructions, mixed with an equal volume of a matrix solution
(10 mg/mL a-cyano-4-hydroxycinnamic acid in 50% acetonitrile/
0.1% TFA), and applied to a target plate. MS/MS analyses were per-
formed using the AB SCIEX TOF/TOF™ 5800 System (AB SCIEX, Fos-
ter City, CA, USA). Protein identiﬁcation was performed with the
ProteinPilot™ software (AB Sciex) using the UniProt database.
2.5. Western blotting
The cytoplasmic and nuclear extracts were isolated using NE-
PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford,
IL, USA). The protein extracts were then separated on 5–20% SDS–
PAGE gels (e-PAGEL; ATTO, Tokyo, Japan) and electrotransferred to
Immobilon-P membranes (Millipore). The membranes were
blocked in Block Ace (DS Parma Biomedical Co. Ltd., Osaka, Japan)
for 1 h and then incubated with a primary antibody in Tris-buf-
fered saline-Tween 20 with 5% Block Ace for 12 h at 4 C. Bands
were visualized with EzWestLumi plus (ATTO).
2.6. Analysis of LPA (18:1) by liquid chromatography–tandem mass
spectrometry
Total lipids were extracted from whole cells by the use of buta-
nol. The samples were diluted to 1:1000 in methanol/water (95:5,
v/v) containing 5 mM ammonium formate, and the amount of LPA
(18:1) was measured by liquid chromatography–tandem mass
spectrometry (LC–MS/MS). The LC–MS/MS was performed using a
quadrupole–linear ion trap hybrid MS, 5500 QTRAP (Applied Bio-
systems/AB Sciex, Concord, ON, Canada), with an Agilent 1200 LC
system combined with an autosampler (Agilent Technologies, Wil-
mington, DE, USA). The LPA (18:1) was separated on an Inertsil
ODS-3 column (150 mm  2.1 mm; with 3 lm silica particles; GL
Sciences Inc., Tokyo, Japan), which was eluted with methanol/
water (95:5, v/v) containing 5 mM ammonium formate at a ﬂow
rate of 0.2 mL/min. Aliquots (10 lL) of the test solutions were
applied to the mass spectrometer for analysis. The LPA (18:1)
was analyzed by multiple reaction monitoring in the negative-
ion mode, with Q3 (product ion) set at m/z 281.2 in combination
with the deprotonated molecular ion as Q1 (m/z 435.16). The rela-
tive amount of LPA (18:1) was calculated from the ratios of the
peak areas using Analyst software (AB SCIEX).
A0.2 
0.4 
0.6
0.8 
1.0 
1.2 
1.4 
0
(FA
BP
3/
18
S-
rR
NA
) 
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
LPA18:1 [µM] 1 5 10 0 30 
-β-actin
-FABP3
1 5 10 0 30 
LPA18:1 [µM]
B
0.2 
0.4 
0.6
0.8 
1.0 
1.2 
1.4 
0
(FA
BP
3/
18
S-
rR
NA
) 
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
Time [h] 6 12 24 0 48
-β-actin
-FABP3
6 12 24 0 48
Time [h]
N.S.
N.S.
Fig. 2. Lysophosphatidic acid (LPA) is not involved in heart-type fatty-acid-binding protein (FABP3) up-regulation in human coronary artery endothelial cells (HCAECs). (A)
Real-time PCRmeasurement of FABP3 mRNA and protein expression in HCAECs. Cells were treated with vehicle (dimethyl sulfoxide) or LPA for 20 h. PCR was performed using
speciﬁc primers for FABP3. The relative FABP3 levels were normalized to 18S rRNA and are expressed as the mean ± SEM (n = 3). Protein levels were analyzed by SDS–PAGE
and visualized with the enhanced chemiluminescence reagent. Each lane was loaded with 20 lg of whole-cell lysate. b-Actin was used as the loading control. (B) Cells were
treated with vehicle (dimethyl sulfoxide), or LPA for 0, 6, 12, 24, and 48 h. PCR was performed using speciﬁc primers for FABP3. The relative FABP3 levels were normalized to
18S rRNA and are expressed as the mean ± SEM (n = 3). Protein levels were analyzed by SDS–PAGE and visualized with the enhanced chemiluminescence reagent. Each lane
was loaded with 20 lg of whole-cell lysate. b-Actin was used as the loading control.
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Total RNA was prepared from HCAECs cells using NucleoSpin
RNA II (Takara, Shiga, Japan). Then, 0.5 lg of total RNA was used
for the subsequent synthesis of cDNA using the ReverTra Ace qPCR
RT Kit (Toyobo, Osaka, Japan) as recommended by the manufac-
turer. mRNA levels were quantiﬁed by using an ECO Real-Time
PCR system (Illumina, Inc., San Diego, CA, USA) and the SYBR Green
Realtime PCR Master Mix Plus (Toyobo) with the following prim-
ers: CD36, 50-GGCTGTGACCGGAACTGTG-30 (F) and 50-AGGTCT
CCAACTGGCATTAGAA-30 (R), and CYP27A1, 50-CGGCAACGGAG
CTTAGAGG-30 (F) and 50-GGCATAGCCTTGAACGAACAG-30 (R) Prim-
ers from a human housekeeping gene primer set (Takara) were
used as the internal control; the most suitable housekeeping genes
were determined according to the manufacturer’s instructions. All
PCRs were performed in 10-lL volumes using 48-well PCR plates
(Illumina, Hayward, CA, USA). The cycling conditions were 95 C
for 10 min (polymerase activation) followed by 40 cycles of 95 C
for 15 s, 55 C for 15 s, and 72 C for 30 s. The relative mRNA quan-
tiﬁcation was calculated using the arithmetic formula 2DDCq,
where DCq is the difference between the threshold cycle of a given
target cDNA and an endogenous reference cDNA.
3. Results
Using afﬁnity chromatography with LPA beads, we successfully
captured a potential target protein (15 kDa) from the HCAECs
(Fig. 1A). After extensive washing, the 15-kDa protein was excised
from the gel, trypsin-digested, and analyzed by peptide mass ﬁn-
gerprinting with MALDI-TOF-MS. Tandem mass spectrometry pro-
ﬁles identifying the FABP3 protein are shown in Fig. 1A. To obtaindirect proof of the interaction of LPA with FABP3, the LPA beads
were incubated with HCAECs extracts in the presence or absence
of 0–30 lM LPA or LPC on ice. The modiﬁed FABP3 was isolated
from the free LPA or LPC, and then subjected to SDS–PAGE and
western blotting against FABP3 antibody. As shown in Fig. 1B,
the LPA-bead-bound FABP3 decreased dose-dependently in the
presence of excess LPA, but not LPC. This result suggests that LPA
interacts with the binding within the FABP3. Next, to determine
the role of LPA in regulating FABP3 expression, we examined the
effect of LPA on FABP3 expression in HCAECs. As shown in
Fig. 2A and 2B, stimulation with LPA (0–30 lM) did not up-regu-
late the FABP3 mRNA and protein expressions. We then veriﬁed
whether the protein involved in the LPA-mediated PPARc activa-
tion was indeed FABP3. As shown in Fig. 3A, the knockdown of
FABP3 expression in HCAECs using small interfering RNA (siRNA)
was effective, as evidenced by real-time polymerase chain reaction
(PCR) analysis and western blot analysis using an anti-FABP3 anti-
body. Real-time PCR analysis showed that FABP3 mRNA in siRNA-
transfected cells was knocked down by 75–80% compared with the
expression in control cells. As shown in Fig. 3B, the knockdown of
FABP3 in HCAECs markedly decreased the ability of the LPA to
induce PPARc-mediated transactivation in a dose-dependent man-
ner. Furthermore, we selected two PPAR target genes and moni-
tored their transcriptional regulation in HCAEC treated with LPA
for 20 h. LPA stimulation activated the expression of Cd36, and
Cyp27a1 by 1.5- to 2-fold (Fig. 3C).
These results suggest that FABP3 enhances the activity of
PPARc. We then examined the amount of LPA present in the
HCAECs. LPA was exogenously added to cells at a concentration
of 10 lM, and LPA uptake was determined by LC–MS/MS. As shown
in Fig. 4B, interestingly, the nuclear fraction of the FABP3-knocked-
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Fig. 3. (A) The effect of small interfering RNA on heart-type fatty-acid-binding protein (FABP3) mRNA expression in human coronary artery endothelial cells (HCAECs). The
efﬁciency of FABP3 knockdown was calculated to be 75% by real-time quantitative RT-PCR. Data are presented as the mean ± SEM (n = 3). Protein levels were analyzed by
SDS–PAGE and visualized with the enhanced chemiluminescence reagent. Each lane was loaded with 20 lg of whole-cell lysate. b-Actin was used as the loading control. (B)
Effect of lysophosphatidic acid (LPA) on reporter activation in FABP3-knocked-down HCAECs. FABP3-knocked-down cells were transiently transfected with a pGL3-PPRE-
acyl-CoA oxidase luciferase reporter vector. The cells were treated with 1–30 lM LPA for 20 h. Luciferase activity was normalized to Renilla luciferase activity. The synthetic
peroxisome proliferator-activated receptor gamma antagonist T0070907 (10 lM) was used as the positive control. Data are expressed as the mean ± SEM (n = 4), ⁄⁄P < 0.01.
(C) Induction of LPA-induced expression of PPARc-regulated genes by in HCAEC. Cells were exposed to a 10 lM LPA or 10 lM T0070907 for 20 h, and RNA was isolated. mRNA
levels for the PPARc upregulated (Cd36, and Cyp27a1) gene targets were determined by real-time quantitative RT-PCR. Relative mRNA abundance ±SEM; n = 3; representative
experiment shown.
950 R. Tsukahara et al. / FEBS Open Bio 4 (2014) 947–951down HCAECs had signiﬁcantly less nuclear LPA than that of the
control cells.
4. Discussion
Relatively few intracellular binding partners for LPA have been
recognized. Previous studies have identiﬁed some candidate pro-
teins, including C-terminal-binding protein/brefeldin A-dependent
ADP ribosylated substrate [17], liver fatty-acid-binding protein
[18], and gelsolin [19]. LPA and alkyl-LPA are also ligands for PPARc[20,21]. Here, the isolation and puriﬁcation of LPA-binding proteins
from HCAECs were coupled to their identiﬁcation by proteomics
technique. As a result, we provided evidence that FABP3 is distrib-
uted from the cytosol to the nucleus in response to LPA-mediated
PPARcactivation. It isbecoming increasinglyapparent that liver spe-
ciﬁc FABPs act as solubilizing intracellular shuttles for fatty acid
ligands to the nucleus, where the ligand is released to its target
PPARs [22]. The lowwater solubilityof LPA in thehydrophilic cytosol
is its diffusionalbarrier. Toobviate this, intracellular proteins suchas
FABPs orchestrate themovement of fatty acids inside cell. Our study
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Fig. 4. Liquid chromatography–electrospray ionization-mass spectrometry (LC–
ESI-MS) quantiﬁcation of lysophosphatidic acid (LPA; 18:1) in the nuclear fraction
of human coronary artery endothelial cells. (A) The nuclear and cytosolic extracts
(20 lg each) were analyzed by western blotting using speciﬁc antibodies against
histone-H3 (nuclear marker) and glyceraldehyde 3-phosphate dehydrogenase
(cytoplasmic marker). (B) The samples were diluted to 1:1000 in methanol/water
(95:5, v/v) containing 5 mM ammonium formate, and the amount of LPA (18:1) was
measured by LC–MS/MS. LC–MS/MS was performed using a quadrupole–linear ion
trap hybrid MS, 5500 QTRAP system. Data are expressed as the intensity; n = 3.
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may therefore serve as intracellular carriers for LPA. We found that
LPA is rapidly and efﬁciently delivered to the nucleus. Such a carrier
function is expected to be more efﬁcient than the free diffusion of
LPA across the cytosol of endocytic vesicles. The function of FABP3
as an LPA carrierwas revealed by the siRNAknockdownexperiment.
Cells transfectedwith FABP3 siRNA showeda relatively slownuclear
transport of LPA comparedwith thewild-type control cells. Further-
more, the reporter gene assay suggested that FABP3 governs the
transcriptional activities of LPA by targeting them to cognate PPARc
in the nucleus. FABP3 shuttles LPA to the nucleus,wherein they acti-
vate PPARc. This hypothesis is supported by a recent report that
FABP5 mediated the nuclear translocation of retinoic acid and
enhanced its activation of PPARs [23]. In conclusion, FABP3 repre-
sents the ﬁrst protein known to transport LPA from the cytosol to
the nucleus in human coronary artery endothelial cells.
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